Menu
Search
|

Menu

Close
X

SAGE Therapeutics Inc SAGE.OQ (NASDAQ Stock Exchange Global Market)

162.37 USD
-1.23 (-0.75%)
As of Feb 16
chart
Previous Close 163.60
Open 160.01
Volume 172,236
3m Avg Volume 291,721
Today’s High 163.75
Today’s Low 159.40
52 Week High 195.97
52 Week Low 57.17
Shares Outstanding (mil) 37.44
Market Capitalization (mil) 2,399.97
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-3.402
FY16
-4.693
FY15
-3.383
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
9.22
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-85.13
14.43
Return on Equity (TTM)
vs sector
-85.28
16.13

EXECUTIVE LEADERSHIP

Kevin Starr
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jeffrey Jonas
President, Chief Executive Officer, Director, Since 2013
Salary: $486,000.00
Bonus: --
Kimi Iguchi
Chief Financial Officer, Treasurer, Since 2016
Salary: $324,480.00
Bonus: --
Anne Cook
Senior Vice President, General Counsel, Since 2016
Salary: $363,694.00
Bonus: --
Amy Schacterle
Senior Vice President - Regulatory Affairs and Quality Assurance, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

215 1st St
CAMBRIDGE   MA   02142-1213

Phone: +1617.2998380

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

SPONSORED STORIES